Fig. 4From: Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trialsForest plots of any grade (A) and grade 3–5 TRAEs (B)Back to article page